Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study

INTRODUCTION: Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with severe persistent allergic asthma. AIM: To demonstrate the quality of life in children with severe asthma and their c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sztafińska, Anna, Jerzyńska, Joanna, Stelmach, Włodzimierz, Woicka-Kolejwa, Katarzyna, Stelmach, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831278/
https://www.ncbi.nlm.nih.gov/pubmed/29507558
http://dx.doi.org/10.5114/ada.2017.71109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831278/
https://www.ncbi.nlm.nih.gov/pubmed/29507558
http://dx.doi.org/10.5114/ada.2017.71109

Ejemplares similares